Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times

Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times The schedule in dosing of intravesical chemotherapy has thus far received little attention. Correlation of optimal contact time with bladder toxicity, as well as maximal chemotherapeutic effect for one of the drugs of first choice for intravesical instillation, i.e. mitomycin C (MMC), is a particularly important question. In a randomized study, we treated bladder cancer patients with intravesical MMC using 30‐min and 60‐min dwelling times. There were 28 evaluable patients in each of the 2 groups. The groups were comparable with respect to mean age, sex ratio and distribution of primary or recurrent and single or multiple tumors. Stages and grades of tumors were also comparable over both treatment groups. Pharmacokinetics of MMC and degradation/metabolism were monitored during the first 4 cycles and the last (8th) cycle using HPLC and mass spectrometry. Recurrence was significantly lower in the 60‐min treatment group (35.7% vs. 14.3%, x2 test; 0.01 < p < 0.05). No recurrences were found in patients with Ta and Tl tumors when the 60‐min dwelling time was used. Toxicity was mild and transient; the incidence was, surprisingly, lower in the 60‐min group but the difference failed to reach the level of significance. Pharmacokinetics of systemic MMC and recovery in the urine was comparable over both groups and systemic absorption was calculated to be in the range of 1–5%. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Cancer Wiley

Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times

Download PDF
6 pages

Loading next page...
 
/lp/wiley/pharmacodynamics-and-pharmacokinetics-of-intravesical-mitomycin-c-upon-jp3V5xCYZ0

References (21)

Publisher
Wiley
Copyright
Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company
ISSN
0020-7136
eISSN
1097-0215
DOI
10.1002/ijc.2910510305
Publisher site
See Article on Publisher Site

Abstract

The schedule in dosing of intravesical chemotherapy has thus far received little attention. Correlation of optimal contact time with bladder toxicity, as well as maximal chemotherapeutic effect for one of the drugs of first choice for intravesical instillation, i.e. mitomycin C (MMC), is a particularly important question. In a randomized study, we treated bladder cancer patients with intravesical MMC using 30‐min and 60‐min dwelling times. There were 28 evaluable patients in each of the 2 groups. The groups were comparable with respect to mean age, sex ratio and distribution of primary or recurrent and single or multiple tumors. Stages and grades of tumors were also comparable over both treatment groups. Pharmacokinetics of MMC and degradation/metabolism were monitored during the first 4 cycles and the last (8th) cycle using HPLC and mass spectrometry. Recurrence was significantly lower in the 60‐min treatment group (35.7% vs. 14.3%, x2 test; 0.01 < p < 0.05). No recurrences were found in patients with Ta and Tl tumors when the 60‐min dwelling time was used. Toxicity was mild and transient; the incidence was, surprisingly, lower in the 60‐min group but the difference failed to reach the level of significance. Pharmacokinetics of systemic MMC and recovery in the urine was comparable over both groups and systemic absorption was calculated to be in the range of 1–5%.

Journal

International Journal of Cancer – Wiley

Published: May 28, 1992

There are no references for this article.